[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcbXclfmT5J6lvOmy1O01jd05wGsGE_owIaMT6Swju6c":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Nova Scotia Health Authority",[4],257,false,89,15,63191,21,202,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Stroke",10,{"name":18,"count":19},"Major Depressive Disorder",7,{"name":21,"count":22},"Bipolar Disorder",5,{"name":24,"count":22},"Frailty",{"name":26,"count":22},"Psychosis",{"name":28,"count":29},"Anesthesia",4,{"name":31,"count":29},"Psychotic Disorders",{"name":33,"count":29},"Schizophrenia",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05708521","Personalization of Opioid Prescription Following Orthognathic Surgery","2024-05-30","Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT02460133","Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment","2025-10","Paritaprevir",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05276856","Recovery Rate in Secondary Hypothyroidism","2025-12-31","Levothyroxine",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT02752542","Personalized Indications for CBT and Antidepressants in Treating Depression","2026-06","Pharmacotherapy",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT05148494","TES RCT Fleet Enema vs Oral Mechanical Bowel Prep","2026-08-01","Fleet Enema",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07001878","Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis","2026-08-31","Metformin",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT03910010","Brain Imaging Study on Biomarkers for Fibromyalgia","2027-02","Placebos",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT07239999","Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total Knee Arthroplasty","2027-04-04","Mepivacaine",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT07272902","Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication","2027-10","Rate Control Medications",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT05821686","Efficacy of Interleukin-2 in Triple Negative Breast Cancer","2028-04","Human Interleukin-2",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,122,146,164,186,212,230,252,276,294,320,338,356,374,392,419,437,457,482,503,525,550,601,637,659,677,699,727,745,769,794,818,841,868,886,911,929,957,975,1001,1026,1048,1073,1099,1117,1135,1161,1184,1209,1236,1259,1282,1307,1333,1361,1379,1402,1420,1446,1464,1482,1507,1531,1555,1582,1612,1636,1654,1678,1702,1727,1753,1777],{"intervention":94,"totalTrials":95,"cells":96},"Lemborexant 5 MG",1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":120},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":95,"conditions":115,"interventions":119},"NCT06093126","Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial","RECRUITING",[90],"2028-12-11","2023-12-11",[116,117,118],"Insomnia","Dementia","Frontotemporal Dementia",[94],{"trials":121,"activeCount":99},[],{"intervention":59,"totalTrials":95,"cells":123},{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":132,"NA":144},{"trials":125,"activeCount":99},[],{"trials":127,"activeCount":99},[],{"trials":129,"activeCount":99},[],{"trials":131,"activeCount":99},[],{"trials":133,"activeCount":95,"soonestReadout":58},[134],{"nctId":56,"briefTitle":57,"status":111,"phases":135,"primaryCompletion":58,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":142},[90],"2026-10-01","2022-03-16",66,[140,141],"Colorectal Neoplasms","Surgery",[59,143],"Pico-Salax",{"trials":145,"activeCount":99},[],{"intervention":143,"totalTrials":95,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":162},{"trials":149,"activeCount":99},[],{"trials":151,"activeCount":99},[],{"trials":153,"activeCount":99},[],{"trials":155,"activeCount":99},[],{"trials":157,"activeCount":95,"soonestReadout":58},[158],{"nctId":56,"briefTitle":57,"status":111,"phases":159,"primaryCompletion":58,"completion":136,"start":137,"enrollment":138,"conditions":160,"interventions":161},[90],[140,141],[59,143],{"trials":163,"activeCount":99},[],{"intervention":64,"totalTrials":95,"cells":165},{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":184},{"trials":167,"activeCount":99},[],{"trials":169,"activeCount":99},[],{"trials":171,"activeCount":99},[],{"trials":173,"activeCount":99},[],{"trials":175,"activeCount":95,"soonestReadout":63},[176],{"nctId":61,"briefTitle":62,"status":111,"phases":177,"primaryCompletion":63,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},[90],"2026-12-01","2025-03-18",24,[26,182],"Cannabis Use",[64],{"trials":185,"activeCount":99},[],{"intervention":187,"totalTrials":95,"cells":188},"Escitalopram",{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":210},{"trials":190,"activeCount":99},[],{"trials":192,"activeCount":99},[],{"trials":194,"activeCount":99},[],{"trials":196,"activeCount":99},[],{"trials":198,"activeCount":95,"soonestReadout":203},[199],{"nctId":200,"briefTitle":201,"status":111,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":208},"NCT05017311","Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)",[90],"2028-12-31","2029-04-30","2023-01-20",400,[18],[187,209],"Brexpiprazole",{"trials":211,"activeCount":99},[],{"intervention":209,"totalTrials":95,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":228},{"trials":215,"activeCount":99},[],{"trials":217,"activeCount":99},[],{"trials":219,"activeCount":99},[],{"trials":221,"activeCount":99},[],{"trials":223,"activeCount":95,"soonestReadout":203},[224],{"nctId":200,"briefTitle":201,"status":111,"phases":225,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":226,"interventions":227},[90],[18],[187,209],{"trials":229,"activeCount":99},[],{"intervention":54,"totalTrials":95,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":250},{"trials":233,"activeCount":99},[],{"trials":235,"activeCount":99},[],{"trials":237,"activeCount":99},[],{"trials":239,"activeCount":99},[],{"trials":241,"activeCount":95,"soonestReadout":53},[242],{"nctId":51,"briefTitle":52,"status":111,"phases":243,"primaryCompletion":53,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":249},[90],"2027-06","2016-10-31",80,[18,248],"Persistent Depressive Disorder",[54],{"trials":251,"activeCount":99},[],{"intervention":74,"totalTrials":95,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":274},{"trials":255,"activeCount":99},[],{"trials":257,"activeCount":99},[],{"trials":259,"activeCount":99},[],{"trials":261,"activeCount":99},[],{"trials":263,"activeCount":95,"soonestReadout":73},[264],{"nctId":71,"briefTitle":72,"status":265,"phases":266,"primaryCompletion":73,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NOT_YET_RECRUITING",[90],"2027-06-15","2026-03-31",170,[271,28],"Recovery Period",[74,273],"Chloroprocaine",{"trials":275,"activeCount":99},[],{"intervention":273,"totalTrials":95,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":292},{"trials":279,"activeCount":99},[],{"trials":281,"activeCount":99},[],{"trials":283,"activeCount":99},[],{"trials":285,"activeCount":99},[],{"trials":287,"activeCount":95,"soonestReadout":73},[288],{"nctId":71,"briefTitle":72,"status":265,"phases":289,"primaryCompletion":73,"completion":267,"start":268,"enrollment":269,"conditions":290,"interventions":291},[90],[271,28],[74,273],{"trials":293,"activeCount":99},[],{"intervention":44,"totalTrials":95,"cells":295},{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":304,"NA":318},{"trials":297,"activeCount":99},[],{"trials":299,"activeCount":99},[],{"trials":301,"activeCount":99},[],{"trials":303,"activeCount":99},[],{"trials":305,"activeCount":95,"soonestReadout":43},[306],{"nctId":41,"briefTitle":42,"status":307,"phases":308,"primaryCompletion":43,"completion":43,"start":309,"enrollment":310,"conditions":311,"interventions":313},"ACTIVE_NOT_RECRUITING",[90],"2015-07-10",44,[312],"Hepatitis C Virus",[44,314,315,316,317],"Ritonavir","Dasabuvir","Ombitasvir","Ribavirin",{"trials":319,"activeCount":99},[],{"intervention":314,"totalTrials":95,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":330,"NA":336},{"trials":323,"activeCount":99},[],{"trials":325,"activeCount":99},[],{"trials":327,"activeCount":99},[],{"trials":329,"activeCount":99},[],{"trials":331,"activeCount":95,"soonestReadout":43},[332],{"nctId":41,"briefTitle":42,"status":307,"phases":333,"primaryCompletion":43,"completion":43,"start":309,"enrollment":310,"conditions":334,"interventions":335},[90],[312],[44,314,315,316,317],{"trials":337,"activeCount":99},[],{"intervention":315,"totalTrials":95,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":354},{"trials":341,"activeCount":99},[],{"trials":343,"activeCount":99},[],{"trials":345,"activeCount":99},[],{"trials":347,"activeCount":99},[],{"trials":349,"activeCount":95,"soonestReadout":43},[350],{"nctId":41,"briefTitle":42,"status":307,"phases":351,"primaryCompletion":43,"completion":43,"start":309,"enrollment":310,"conditions":352,"interventions":353},[90],[312],[44,314,315,316,317],{"trials":355,"activeCount":99},[],{"intervention":316,"totalTrials":95,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":372},{"trials":359,"activeCount":99},[],{"trials":361,"activeCount":99},[],{"trials":363,"activeCount":99},[],{"trials":365,"activeCount":99},[],{"trials":367,"activeCount":95,"soonestReadout":43},[368],{"nctId":41,"briefTitle":42,"status":307,"phases":369,"primaryCompletion":43,"completion":43,"start":309,"enrollment":310,"conditions":370,"interventions":371},[90],[312],[44,314,315,316,317],{"trials":373,"activeCount":99},[],{"intervention":317,"totalTrials":95,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":384,"NA":390},{"trials":377,"activeCount":99},[],{"trials":379,"activeCount":99},[],{"trials":381,"activeCount":99},[],{"trials":383,"activeCount":99},[],{"trials":385,"activeCount":95,"soonestReadout":43},[386],{"nctId":41,"briefTitle":42,"status":307,"phases":387,"primaryCompletion":43,"completion":43,"start":309,"enrollment":310,"conditions":388,"interventions":389},[90],[312],[44,314,315,316,317],{"trials":391,"activeCount":99},[],{"intervention":39,"totalTrials":95,"cells":393},{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":400,"PHASE4":402,"NA":417},{"trials":395,"activeCount":99},[],{"trials":397,"activeCount":99},[],{"trials":399,"activeCount":99},[],{"trials":401,"activeCount":99},[],{"trials":403,"activeCount":95,"soonestReadout":38},[404],{"nctId":36,"briefTitle":37,"status":307,"phases":405,"primaryCompletion":38,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":415},[90],"2026-05-01","2023-04-24",201,[410,411,412,413,414],"Pain, Postoperative","Orthognathic Surgery","Opioid Use","Patient Satisfaction","Opioid Use Disorder",[39,416],"Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery",{"trials":418,"activeCount":99},[],{"intervention":416,"totalTrials":95,"cells":420},{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":435},{"trials":422,"activeCount":99},[],{"trials":424,"activeCount":99},[],{"trials":426,"activeCount":99},[],{"trials":428,"activeCount":99},[],{"trials":430,"activeCount":95,"soonestReadout":38},[431],{"nctId":36,"briefTitle":37,"status":307,"phases":432,"primaryCompletion":38,"completion":406,"start":407,"enrollment":408,"conditions":433,"interventions":434},[90],[410,411,412,413,414],[39,416],{"trials":436,"activeCount":99},[],{"intervention":84,"totalTrials":95,"cells":438},{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":451,"PHASE4":453,"NA":455},{"trials":440,"activeCount":99},[],{"trials":442,"activeCount":99},[],{"trials":444,"activeCount":95,"soonestReadout":83},[445],{"nctId":81,"briefTitle":82,"status":265,"phases":446,"primaryCompletion":83,"completion":83,"start":447,"enrollment":16,"conditions":448,"interventions":450},[87,88],"2026-01-02",[449],"Triple Negative Breast Cancer",[84],{"trials":452,"activeCount":99},[],{"trials":454,"activeCount":99},[],{"trials":456,"activeCount":99},[],{"intervention":458,"totalTrials":95,"cells":459},"Antidepressant medication",{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":476,"PHASE4":478,"NA":480},{"trials":461,"activeCount":99},[],{"trials":463,"activeCount":99},[],{"trials":465,"activeCount":95,"soonestReadout":470},[466],{"nctId":467,"briefTitle":468,"status":111,"phases":469,"primaryCompletion":470,"completion":203,"start":471,"enrollment":472,"conditions":473,"interventions":475},"NCT05002309","Treatment Interrupts Depression Early",[88],"2028-06-30","2021-12-02",100,[474],"Depression",[458],{"trials":477,"activeCount":99},[],{"trials":479,"activeCount":99},[],{"trials":481,"activeCount":99},[],{"intervention":49,"totalTrials":95,"cells":483},{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":485,"activeCount":99},[],{"trials":487,"activeCount":99},[],{"trials":489,"activeCount":99},[],{"trials":491,"activeCount":99},[],{"trials":493,"activeCount":99},[],{"trials":495,"activeCount":95,"soonestReadout":48},[496],{"nctId":46,"briefTitle":47,"status":111,"phases":497,"primaryCompletion":48,"completion":48,"start":498,"enrollment":499,"conditions":500,"interventions":502},[],"2022-04-04",90,[501],"Secondary Hypothyroidism",[49],{"intervention":69,"totalTrials":95,"cells":504},{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":511,"PHASE4":513,"NA":515},{"trials":506,"activeCount":99},[],{"trials":508,"activeCount":99},[],{"trials":510,"activeCount":99},[],{"trials":512,"activeCount":99},[],{"trials":514,"activeCount":99},[],{"trials":516,"activeCount":95,"soonestReadout":68},[517],{"nctId":66,"briefTitle":67,"status":111,"phases":518,"primaryCompletion":68,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":524},[91],"2035-01","2021-02-01",35,[523],"Fibromyalgia",[69],{"intervention":79,"totalTrials":95,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":535,"NA":537},{"trials":528,"activeCount":99},[],{"trials":530,"activeCount":99},[],{"trials":532,"activeCount":99},[],{"trials":534,"activeCount":99},[],{"trials":536,"activeCount":99},[],{"trials":538,"activeCount":95,"soonestReadout":78},[539],{"nctId":76,"briefTitle":77,"status":111,"phases":540,"primaryCompletion":78,"completion":78,"start":541,"enrollment":542,"conditions":543,"interventions":549},[91],"2026-01-01",84,[544,545,546,547,548],"Atrial Fibrillation (AF)","Heart Failure With Mildly Reduced Ejection Fraction","Heart Failure With Preserved Ejection Fraction (HFPEF)","Rate Control","Rhythm Control",[79],{"intervention":551,"totalTrials":552,"cells":553},"Normal Saline",3,{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":584,"PHASE4":586,"NA":599},{"trials":555,"activeCount":99},[],{"trials":557,"activeCount":99},[],{"trials":559,"activeCount":99},[560,572],{"nctId":561,"briefTitle":562,"status":563,"phases":564,"primaryCompletion":565,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":570},"NCT01177358","Botox in the Healing of Surgical Wounds of the Neck","COMPLETED",[88],"2016-05-05","2010-05-31",40,[569],"Scar",[571,551],"Botulinum Toxin Type A",{"nctId":573,"briefTitle":574,"status":575,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":99,"conditions":579,"interventions":582},"NCT04270019","Polyethylene Glycol to Improve Sensation Following Digital Nerve Laceration","WITHDRAWN",[87,88],"2023-09-15","2020-06-26",[580,581],"Peripheral Nerve Injury","Nerve Injury",[583,551],"Polyethylene Glycol 3350",{"trials":585,"activeCount":99},[],{"trials":587,"activeCount":99},[588],{"nctId":589,"briefTitle":590,"status":575,"phases":591,"primaryCompletion":592,"completion":593,"start":594,"enrollment":99,"conditions":595,"interventions":597},"NCT03007381","Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn",[90],"2019-01","2019-06","2017-11",[596],"Breast Cancer Female",[598,551],"Ketorolac Tromethamine",{"trials":600,"activeCount":99},[],{"intervention":602,"totalTrials":603,"cells":604},"Lithium",2,{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":624,"NA":635},{"trials":606,"activeCount":99},[],{"trials":608,"activeCount":99},[],{"trials":610,"activeCount":99},[],{"trials":612,"activeCount":99},[613],{"nctId":614,"briefTitle":615,"status":616,"phases":617,"primaryCompletion":618,"completion":618,"start":619,"enrollment":603,"conditions":620,"interventions":621},"NCT00400088","Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide","TERMINATED",[89],"2013-01","2007-06",[18],[622,623],"paroxetine","lithium",{"trials":625,"activeCount":99},[626],{"nctId":627,"briefTitle":628,"status":575,"phases":629,"primaryCompletion":630,"completion":630,"start":631,"enrollment":99,"conditions":632,"interventions":633},"NCT01416220","Lithium Versus Paroxetine in Major Depression",[90],"2013-02","2011-09",[18],[602,634],"Paroxetine",{"trials":636,"activeCount":99},[],{"intervention":634,"totalTrials":603,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":651,"NA":657},{"trials":640,"activeCount":99},[],{"trials":642,"activeCount":99},[],{"trials":644,"activeCount":99},[],{"trials":646,"activeCount":99},[647],{"nctId":614,"briefTitle":615,"status":616,"phases":648,"primaryCompletion":618,"completion":618,"start":619,"enrollment":603,"conditions":649,"interventions":650},[89],[18],[622,623],{"trials":652,"activeCount":99},[653],{"nctId":627,"briefTitle":628,"status":575,"phases":654,"primaryCompletion":630,"completion":630,"start":631,"enrollment":99,"conditions":655,"interventions":656},[90],[18],[602,634],{"trials":658,"activeCount":99},[],{"intervention":598,"totalTrials":95,"cells":660},{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":675},{"trials":662,"activeCount":99},[],{"trials":664,"activeCount":99},[],{"trials":666,"activeCount":99},[],{"trials":668,"activeCount":99},[],{"trials":670,"activeCount":99},[671],{"nctId":589,"briefTitle":590,"status":575,"phases":672,"primaryCompletion":592,"completion":593,"start":594,"enrollment":99,"conditions":673,"interventions":674},[90],[596],[598,551],{"trials":676,"activeCount":99},[],{"intervention":678,"totalTrials":95,"cells":679},"TCA",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":697},{"trials":681,"activeCount":99},[],{"trials":683,"activeCount":99},[],{"trials":685,"activeCount":99},[],{"trials":687,"activeCount":99},[],{"trials":689,"activeCount":99},[690],{"nctId":691,"briefTitle":692,"status":575,"phases":693,"primaryCompletion":577,"completion":577,"start":577,"enrollment":99,"conditions":694,"interventions":696},"NCT04744103","Trichloroacetic Acid as a Topical Treatment for Actinic Cheilitis",[90],[695],"Actinic Cheilitis",[678],{"trials":698,"activeCount":99},[],{"intervention":700,"totalTrials":95,"cells":701},"Rivaroxaban",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":725},{"trials":703,"activeCount":99},[],{"trials":705,"activeCount":99},[],{"trials":707,"activeCount":99},[],{"trials":709,"activeCount":99},[],{"trials":711,"activeCount":99},[712],{"nctId":713,"briefTitle":714,"status":715,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":723},"NCT05116995","Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients","UNKNOWN",[90],"2023-11-01","2021-11-01",30,[721,722],"Thrombosis","Myocardial Infarction",[700,724],"Ticagrelor",{"trials":726,"activeCount":99},[],{"intervention":724,"totalTrials":95,"cells":728},{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":735,"PHASE4":737,"NA":743},{"trials":730,"activeCount":99},[],{"trials":732,"activeCount":99},[],{"trials":734,"activeCount":99},[],{"trials":736,"activeCount":99},[],{"trials":738,"activeCount":99},[739],{"nctId":713,"briefTitle":714,"status":715,"phases":740,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":741,"interventions":742},[90],[721,722],[700,724],{"trials":744,"activeCount":99},[],{"intervention":746,"totalTrials":95,"cells":747},"mycophenolate mofetil",{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":767},{"trials":749,"activeCount":99},[],{"trials":751,"activeCount":99},[],{"trials":753,"activeCount":99},[],{"trials":755,"activeCount":99},[],{"trials":757,"activeCount":99},[758],{"nctId":759,"briefTitle":760,"status":563,"phases":761,"primaryCompletion":762,"completion":762,"start":763,"enrollment":567,"conditions":764,"interventions":766},"NCT00943228","Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation",[90],"2012-02","2010-02",[765],"Acute Rejection of Renal Transplant",[746],{"trials":768,"activeCount":99},[],{"intervention":770,"totalTrials":95,"cells":771},"Aggressive Blood Pressure control",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":778,"PHASE4":780,"NA":792},{"trials":773,"activeCount":99},[],{"trials":775,"activeCount":99},[],{"trials":777,"activeCount":99},[],{"trials":779,"activeCount":99},[],{"trials":781,"activeCount":99},[782],{"nctId":783,"briefTitle":784,"status":563,"phases":785,"primaryCompletion":786,"completion":786,"start":787,"enrollment":788,"conditions":789,"interventions":791},"NCT00438113","Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF",[90],"2016-09","2009-12",184,[790],"Atrial Fibrillation",[770],{"trials":793,"activeCount":99},[],{"intervention":795,"totalTrials":95,"cells":796},"Ranitidine",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":805,"NA":816},{"trials":798,"activeCount":99},[],{"trials":800,"activeCount":99},[],{"trials":802,"activeCount":99},[],{"trials":804,"activeCount":99},[],{"trials":806,"activeCount":99},[807],{"nctId":808,"briefTitle":809,"status":563,"phases":810,"primaryCompletion":811,"completion":811,"start":812,"enrollment":719,"conditions":813,"interventions":815},"NCT03145012","Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity",[90],"2018-10-24","2018-05-01",[814],"Cancer",[795],{"trials":817,"activeCount":99},[],{"intervention":819,"totalTrials":95,"cells":820},"morphine",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":839},{"trials":822,"activeCount":99},[],{"trials":824,"activeCount":99},[],{"trials":826,"activeCount":99},[],{"trials":828,"activeCount":99},[],{"trials":830,"activeCount":99},[831],{"nctId":832,"briefTitle":833,"status":563,"phases":834,"primaryCompletion":630,"completion":630,"start":835,"enrollment":521,"conditions":836,"interventions":838},"NCT00878371","Effects of a Surgery-induced Peripheral Inflammatory Response on the Blood Brain Barrier",[90],"2009-05",[837],"Dissecting Aneurysm of the Thoracic Aorta",[819],{"trials":840,"activeCount":99},[],{"intervention":842,"totalTrials":95,"cells":843},"Mirabegron",{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":850,"PHASE4":852,"NA":866},{"trials":845,"activeCount":99},[],{"trials":847,"activeCount":99},[],{"trials":849,"activeCount":99},[],{"trials":851,"activeCount":99},[],{"trials":853,"activeCount":99},[854],{"nctId":855,"briefTitle":856,"status":563,"phases":857,"primaryCompletion":858,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":863},"NCT02095665","Ureteral Stent-related Pain and Mirabegron (SPAM) Trial",[90],"2018-03-23","2014-01-01",22,[862],"Nephrolithiasis",[842,864,865],"Tamsulosin","Tylenol #3",{"trials":867,"activeCount":99},[],{"intervention":864,"totalTrials":95,"cells":869},{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":876,"PHASE4":878,"NA":884},{"trials":871,"activeCount":99},[],{"trials":873,"activeCount":99},[],{"trials":875,"activeCount":99},[],{"trials":877,"activeCount":99},[],{"trials":879,"activeCount":99},[880],{"nctId":855,"briefTitle":856,"status":563,"phases":881,"primaryCompletion":858,"completion":858,"start":859,"enrollment":860,"conditions":882,"interventions":883},[90],[862],[842,864,865],{"trials":885,"activeCount":99},[],{"intervention":887,"totalTrials":95,"cells":888},"Methadone",{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":897,"NA":909},{"trials":890,"activeCount":99},[],{"trials":892,"activeCount":99},[],{"trials":894,"activeCount":99},[],{"trials":896,"activeCount":99},[],{"trials":898,"activeCount":99},[899],{"nctId":900,"briefTitle":901,"status":616,"phases":902,"primaryCompletion":903,"completion":903,"start":618,"enrollment":904,"conditions":905,"interventions":907},"NCT01205516","Methadone in Neuropathic Pain",[90],"2017-12",14,[906],"Chronic Neuropathic Pain",[887,908],"Controlled Release Morphine",{"trials":910,"activeCount":99},[],{"intervention":908,"totalTrials":95,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":919,"PHASE4":921,"NA":927},{"trials":914,"activeCount":99},[],{"trials":916,"activeCount":99},[],{"trials":918,"activeCount":99},[],{"trials":920,"activeCount":99},[],{"trials":922,"activeCount":99},[923],{"nctId":900,"briefTitle":901,"status":616,"phases":924,"primaryCompletion":903,"completion":903,"start":618,"enrollment":904,"conditions":925,"interventions":926},[90],[906],[887,908],{"trials":928,"activeCount":99},[],{"intervention":930,"totalTrials":95,"cells":931},"Current Bowel Protocol",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":955},{"trials":933,"activeCount":99},[],{"trials":935,"activeCount":99},[],{"trials":937,"activeCount":99},[],{"trials":939,"activeCount":99},[],{"trials":941,"activeCount":99},[942],{"nctId":943,"briefTitle":944,"status":563,"phases":945,"primaryCompletion":946,"completion":947,"start":948,"enrollment":949,"conditions":950,"interventions":953},"NCT03148002","Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation",[90],"2018-04-01","2018-06-05","2017-07-07",25,[951,952],"Constipation","Peritoneal Dialysis Complication",[930,954],"PEG Bowel Protocol",{"trials":956,"activeCount":99},[],{"intervention":954,"totalTrials":95,"cells":958},{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":965,"PHASE4":967,"NA":973},{"trials":960,"activeCount":99},[],{"trials":962,"activeCount":99},[],{"trials":964,"activeCount":99},[],{"trials":966,"activeCount":99},[],{"trials":968,"activeCount":99},[969],{"nctId":943,"briefTitle":944,"status":563,"phases":970,"primaryCompletion":946,"completion":947,"start":948,"enrollment":949,"conditions":971,"interventions":972},[90],[951,952],[930,954],{"trials":974,"activeCount":99},[],{"intervention":976,"totalTrials":95,"cells":977},"Acetylcysteine",{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":999},{"trials":979,"activeCount":99},[],{"trials":981,"activeCount":99},[],{"trials":983,"activeCount":99},[],{"trials":985,"activeCount":99},[],{"trials":987,"activeCount":99},[988],{"nctId":989,"briefTitle":990,"status":575,"phases":991,"primaryCompletion":992,"completion":992,"start":993,"enrollment":99,"conditions":994,"interventions":998},"NCT02788292","Effect of N-Acetylcysteine on Autologous Fat Graft Survival",[90],"2020-11-16","2016-08-15",[995,996,997],"Adipose Tissue Atrophy","Deformity of Reconstructed Breast","Graft Loss",[976],{"trials":1000,"activeCount":99},[],{"intervention":1002,"totalTrials":95,"cells":1003},"Bevacizumab",{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1012,"NA":1024},{"trials":1005,"activeCount":99},[],{"trials":1007,"activeCount":99},[],{"trials":1009,"activeCount":99},[],{"trials":1011,"activeCount":99},[],{"trials":1013,"activeCount":99},[1014],{"nctId":1015,"briefTitle":1016,"status":575,"phases":1017,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":99,"conditions":1021,"interventions":1023},"NCT01229202","Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery",[90],"2012-12","2016-01","2008-07",[1022],"Glaucoma",[1002],{"trials":1025,"activeCount":99},[],{"intervention":1027,"totalTrials":95,"cells":1028},"Prostagladin",{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1046},{"trials":1030,"activeCount":99},[],{"trials":1032,"activeCount":99},[],{"trials":1034,"activeCount":99},[],{"trials":1036,"activeCount":99},[],{"trials":1038,"activeCount":99},[1039],{"nctId":1040,"briefTitle":1041,"status":575,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1043,"enrollment":99,"conditions":1044,"interventions":1045},"NCT01704989","The Laser in Pseudoexfoliation (LIP) Study",[90],"2012-06",[1022],[1027],{"trials":1047,"activeCount":99},[],{"intervention":1049,"totalTrials":95,"cells":1050},"Iohexol",{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1057,"PHASE4":1059,"NA":1071},{"trials":1052,"activeCount":99},[],{"trials":1054,"activeCount":99},[],{"trials":1056,"activeCount":99},[],{"trials":1058,"activeCount":99},[],{"trials":1060,"activeCount":99},[1061],{"nctId":1062,"briefTitle":1063,"status":563,"phases":1064,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1070},"NCT03415997","Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight",[90],"2018-11-09","2018-02-21",239,[1069],"Contrast Media Dosing",[1049],{"trials":1072,"activeCount":99},[],{"intervention":1074,"totalTrials":95,"cells":1075},"0 L\u002Fmin oxygen via conventional nasal cannulae",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1084,"NA":1097},{"trials":1077,"activeCount":99},[],{"trials":1079,"activeCount":99},[],{"trials":1081,"activeCount":99},[],{"trials":1083,"activeCount":99},[],{"trials":1085,"activeCount":99},[1086],{"nctId":1087,"briefTitle":1088,"status":563,"phases":1089,"primaryCompletion":1090,"completion":1090,"start":786,"enrollment":1091,"conditions":1092,"interventions":1094},"NCT02755389","Apneic Oxygenation Via Nasal Cannulae: 15 L\u002FMin vs High-Flow",[90],"2018-06-22",45,[1093],"Apneic Oxygenation",[1074,1095,1096],"15 L\u002Fmin oxygen via conventional nasal cannulae","60 L\u002Fmin oxygen via high-flow nasal cannulae",{"trials":1098,"activeCount":99},[],{"intervention":1095,"totalTrials":95,"cells":1100},{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1107,"PHASE4":1109,"NA":1115},{"trials":1102,"activeCount":99},[],{"trials":1104,"activeCount":99},[],{"trials":1106,"activeCount":99},[],{"trials":1108,"activeCount":99},[],{"trials":1110,"activeCount":99},[1111],{"nctId":1087,"briefTitle":1088,"status":563,"phases":1112,"primaryCompletion":1090,"completion":1090,"start":786,"enrollment":1091,"conditions":1113,"interventions":1114},[90],[1093],[1074,1095,1096],{"trials":1116,"activeCount":99},[],{"intervention":1096,"totalTrials":95,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1127,"NA":1133},{"trials":1120,"activeCount":99},[],{"trials":1122,"activeCount":99},[],{"trials":1124,"activeCount":99},[],{"trials":1126,"activeCount":99},[],{"trials":1128,"activeCount":99},[1129],{"nctId":1087,"briefTitle":1088,"status":563,"phases":1130,"primaryCompletion":1090,"completion":1090,"start":786,"enrollment":1091,"conditions":1131,"interventions":1132},[90],[1093],[1074,1095,1096],{"trials":1134,"activeCount":99},[],{"intervention":1136,"totalTrials":95,"cells":1137},"Alfuzosin",{"EARLY_PHASE1":1138,"PHASE1":1140,"PHASE2":1142,"PHASE3":1144,"PHASE4":1157,"NA":1159},{"trials":1139,"activeCount":99},[],{"trials":1141,"activeCount":99},[],{"trials":1143,"activeCount":99},[],{"trials":1145,"activeCount":99},[1146],{"nctId":1147,"briefTitle":1148,"status":616,"phases":1149,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":1153,"interventions":1156},"NCT00688948","Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)",[88,89],"2009-11","2007-11",20,[1154,1155],"Multiple Sclerosis","Bladder Dysfunction",[1136],{"trials":1158,"activeCount":99},[],{"trials":1160,"activeCount":99},[],{"intervention":1162,"totalTrials":95,"cells":1163},"Methylene Blue",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1180,"NA":1182},{"trials":1165,"activeCount":99},[],{"trials":1167,"activeCount":99},[],{"trials":1169,"activeCount":99},[],{"trials":1171,"activeCount":99},[1172],{"nctId":1173,"briefTitle":1174,"status":563,"phases":1175,"completion":1176,"start":1177,"enrollment":567,"conditions":1178,"interventions":1179},"NCT00214877","Methylene Blue for Cognitive Dysfunction in Bipolar Disorder",[89],"2007-10","2003-11",[21],[1162],{"trials":1181,"activeCount":99},[],{"trials":1183,"activeCount":99},[],{"intervention":1185,"totalTrials":95,"cells":1186},"Polysaccharide iron complex",{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1193,"PHASE4":1205,"NA":1207},{"trials":1188,"activeCount":99},[],{"trials":1190,"activeCount":99},[],{"trials":1192,"activeCount":99},[],{"trials":1194,"activeCount":99},[1195],{"nctId":1196,"briefTitle":1197,"status":616,"phases":1198,"primaryCompletion":1066,"completion":1199,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1204},"NCT01912261","Effects of Oral Iron on Postoperative Fatigue Upon Coronary Artery Bypass Graft Patients",[89],"2019-02","2014-12-16",121,[1203],"Fatigue",[1185],{"trials":1206,"activeCount":99},[],{"trials":1208,"activeCount":99},[],{"intervention":1210,"totalTrials":95,"cells":1211},"Pregabalin",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1218,"PHASE4":1232,"NA":1234},{"trials":1213,"activeCount":99},[],{"trials":1215,"activeCount":99},[],{"trials":1217,"activeCount":99},[],{"trials":1219,"activeCount":99},[1220],{"nctId":1221,"briefTitle":1222,"status":563,"phases":1223,"primaryCompletion":1224,"completion":1225,"start":1226,"enrollment":1227,"conditions":1228,"interventions":1231},"NCT00852683","The Effects of Peri-Operative Pregabalin on Post-Operative Pain Following Breast Cancer Surgery With Axillary Node Dissection: A Pilot Study",[89],"2013-04","2013-12","2008-05",70,[1229,1230],"Breast Cancer Surgery","Post Operative Pain",[1210],{"trials":1233,"activeCount":99},[],{"trials":1235,"activeCount":99},[],{"intervention":1237,"totalTrials":95,"cells":1238},"Niaspan",{"EARLY_PHASE1":1239,"PHASE1":1241,"PHASE2":1243,"PHASE3":1245,"PHASE4":1255,"NA":1257},{"trials":1240,"activeCount":99},[],{"trials":1242,"activeCount":99},[],{"trials":1244,"activeCount":99},[],{"trials":1246,"activeCount":99},[1247],{"nctId":1248,"briefTitle":1249,"status":563,"phases":1250,"primaryCompletion":1251,"completion":1251,"start":1252,"enrollment":860,"conditions":1253,"interventions":1254},"NCT01720095","Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis",[89],"2014-12","2009-10",[26],[1237],{"trials":1256,"activeCount":99},[],{"trials":1258,"activeCount":99},[],{"intervention":1260,"totalTrials":95,"cells":1261},"Opioid (morphine sulphate) in low dose",{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1268,"PHASE4":1278,"NA":1280},{"trials":1263,"activeCount":99},[],{"trials":1265,"activeCount":99},[],{"trials":1267,"activeCount":99},[],{"trials":1269,"activeCount":99},[1270],{"nctId":1271,"briefTitle":1272,"status":563,"phases":1273,"primaryCompletion":1043,"completion":1043,"start":1274,"enrollment":1091,"conditions":1275,"interventions":1277},"NCT00982891","Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD)",[88,89],"2010-03",[1276],"Chronic Obstructive Pulmonary Disease (COPD)",[1260],{"trials":1279,"activeCount":99},[],{"trials":1281,"activeCount":99},[],{"intervention":1283,"totalTrials":95,"cells":1284},"Intralesional enalaprilat",{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1291,"PHASE4":1303,"NA":1305},{"trials":1286,"activeCount":99},[],{"trials":1288,"activeCount":99},[],{"trials":1290,"activeCount":99},[],{"trials":1292,"activeCount":99},[1293],{"nctId":1294,"briefTitle":1295,"status":575,"phases":1296,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":99,"conditions":1300,"interventions":1302},"NCT05259137","Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars",[88,89],"2026-08","2026-10","2024-08",[1301],"Hypertrophic Scar",[1283],{"trials":1304,"activeCount":99},[],{"trials":1306,"activeCount":99},[],{"intervention":1308,"totalTrials":95,"cells":1309},"Fibrinogen",{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1329,"NA":1331},{"trials":1311,"activeCount":99},[],{"trials":1313,"activeCount":99},[],{"trials":1315,"activeCount":99},[],{"trials":1317,"activeCount":99},[1318],{"nctId":1319,"briefTitle":1320,"status":563,"phases":1321,"primaryCompletion":1322,"completion":1323,"start":1324,"enrollment":1325,"conditions":1326,"interventions":1328},"NCT01623531","Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery",[89],"2019-03-31","2019-06-30","2014-02",62,[1327],"Cardiac Complication During Procedure",[1308],{"trials":1330,"activeCount":99},[],{"trials":1332,"activeCount":99},[],{"intervention":1334,"totalTrials":95,"cells":1335},"acetaminophen plus codeine",{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1342,"PHASE4":1357,"NA":1359},{"trials":1337,"activeCount":99},[],{"trials":1339,"activeCount":99},[],{"trials":1341,"activeCount":99},[],{"trials":1343,"activeCount":99},[1344],{"nctId":1345,"briefTitle":1346,"status":563,"phases":1347,"primaryCompletion":1348,"completion":1349,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1355},"NCT00299039","T3AI-Pain After Breast Surgery",[89],"2008-06","2008-09","2006-05",150,[1353,1354],"Pain","Breast Diseases",[1334,1356],"acetaminophen plus ibuprofen",{"trials":1358,"activeCount":99},[],{"trials":1360,"activeCount":99},[],{"intervention":1356,"totalTrials":95,"cells":1362},{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1367,"PHASE3":1369,"PHASE4":1375,"NA":1377},{"trials":1364,"activeCount":99},[],{"trials":1366,"activeCount":99},[],{"trials":1368,"activeCount":99},[],{"trials":1370,"activeCount":99},[1371],{"nctId":1345,"briefTitle":1346,"status":563,"phases":1372,"primaryCompletion":1348,"completion":1349,"start":1350,"enrollment":1351,"conditions":1373,"interventions":1374},[89],[1353,1354],[1334,1356],{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[],{"intervention":1380,"totalTrials":95,"cells":1381},"Lyrica",{"EARLY_PHASE1":1382,"PHASE1":1384,"PHASE2":1386,"PHASE3":1388,"PHASE4":1398,"NA":1400},{"trials":1383,"activeCount":99},[],{"trials":1385,"activeCount":99},[],{"trials":1387,"activeCount":99},[],{"trials":1389,"activeCount":99},[1390],{"nctId":1391,"briefTitle":1392,"status":616,"phases":1393,"primaryCompletion":1043,"completion":1043,"start":1394,"enrollment":22,"conditions":1395,"interventions":1397},"NCT00879021","Study of Pregabalin in the Prevention of Central Neuropathic Pain in Acute Spinal Cord Injury",[89],"2009-09",[1396,1353],"Spinal Cord Trauma",[1380],{"trials":1399,"activeCount":99},[],{"trials":1401,"activeCount":99},[],{"intervention":571,"totalTrials":95,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1414,"PHASE4":1416,"NA":1418},{"trials":1405,"activeCount":99},[],{"trials":1407,"activeCount":99},[],{"trials":1409,"activeCount":99},[1410],{"nctId":561,"briefTitle":562,"status":563,"phases":1411,"primaryCompletion":565,"completion":565,"start":566,"enrollment":567,"conditions":1412,"interventions":1413},[88],[569],[571,551],{"trials":1415,"activeCount":99},[],{"trials":1417,"activeCount":99},[],{"trials":1419,"activeCount":99},[],{"intervention":1421,"totalTrials":95,"cells":1422},"dimethyl sulfoxide",{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1440,"PHASE4":1442,"NA":1444},{"trials":1424,"activeCount":99},[],{"trials":1426,"activeCount":99},[],{"trials":1428,"activeCount":99},[1429],{"nctId":1430,"briefTitle":1431,"status":616,"phases":1432,"primaryCompletion":1433,"completion":1433,"start":1434,"enrollment":16,"conditions":1435,"interventions":1438},"NCT00317070","Trial Comparing Intravesical Cocktail With Intravesical Dimethyl Sulfoxide (DMSO) in Painful Bladder Syndrome\u002FInterstitial Cystitis (PBS\u002FIC)",[88],"2009-02","2006-04",[1436,1437],"Interstitial Cystitis","Bladder Diseases",[1421,1439],"IC Cocktail",{"trials":1441,"activeCount":99},[],{"trials":1443,"activeCount":99},[],{"trials":1445,"activeCount":99},[],{"intervention":1439,"totalTrials":95,"cells":1447},{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1458,"PHASE4":1460,"NA":1462},{"trials":1449,"activeCount":99},[],{"trials":1451,"activeCount":99},[],{"trials":1453,"activeCount":99},[1454],{"nctId":1430,"briefTitle":1431,"status":616,"phases":1455,"primaryCompletion":1433,"completion":1433,"start":1434,"enrollment":16,"conditions":1456,"interventions":1457},[88],[1436,1437],[1421,1439],{"trials":1459,"activeCount":99},[],{"trials":1461,"activeCount":99},[],{"trials":1463,"activeCount":99},[],{"intervention":583,"totalTrials":95,"cells":1465},{"EARLY_PHASE1":1466,"PHASE1":1468,"PHASE2":1470,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1467,"activeCount":99},[],{"trials":1469,"activeCount":99},[],{"trials":1471,"activeCount":99},[1472],{"nctId":573,"briefTitle":574,"status":575,"phases":1473,"primaryCompletion":577,"completion":577,"start":578,"enrollment":99,"conditions":1474,"interventions":1475},[87,88],[580,581],[583,551],{"trials":1477,"activeCount":99},[],{"trials":1479,"activeCount":99},[],{"trials":1481,"activeCount":99},[],{"intervention":1483,"totalTrials":95,"cells":1484},"Kineret",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1499,"PHASE3":1501,"PHASE4":1503,"NA":1505},{"trials":1486,"activeCount":99},[],{"trials":1488,"activeCount":99},[1489],{"nctId":1490,"briefTitle":1491,"status":563,"phases":1492,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1495,"conditions":1496,"interventions":1498},"NCT00214851","The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria",[87],"2005-12","2005-09",8,[1497],"Familial Cold Urticaria",[1483],{"trials":1500,"activeCount":99},[],{"trials":1502,"activeCount":99},[],{"trials":1504,"activeCount":99},[],{"trials":1506,"activeCount":99},[],{"intervention":1508,"totalTrials":95,"cells":1509},"Lithium Carbonate",{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1523,"PHASE3":1525,"PHASE4":1527,"NA":1529},{"trials":1511,"activeCount":99},[],{"trials":1513,"activeCount":99},[1514],{"nctId":1515,"briefTitle":1516,"status":563,"phases":1517,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":603,"conditions":1520,"interventions":1522},"NCT01565759","In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects",[87],"2023-05-11","2012-05-05",[1521],"Drug Mechanism",[1508],{"trials":1524,"activeCount":99},[],{"trials":1526,"activeCount":99},[],{"trials":1528,"activeCount":99},[],{"trials":1530,"activeCount":99},[],{"intervention":1532,"totalTrials":95,"cells":1533},"Dabigatran Etexilate 110 mg",{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1547,"PHASE3":1549,"PHASE4":1551,"NA":1553},{"trials":1535,"activeCount":99},[],{"trials":1537,"activeCount":99},[1538],{"nctId":1539,"briefTitle":1540,"status":563,"phases":1541,"primaryCompletion":1542,"completion":1542,"start":1543,"enrollment":16,"conditions":1544,"interventions":1546},"NCT01590823","An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients",[87],"2012-09","2012-07",[1545],"Blood Coagulation Disorders",[1532],{"trials":1548,"activeCount":99},[],{"trials":1550,"activeCount":99},[],{"trials":1552,"activeCount":99},[],{"trials":1554,"activeCount":99},[],{"intervention":1556,"totalTrials":95,"cells":1557},"Glycerol",{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1574,"PHASE3":1576,"PHASE4":1578,"NA":1580},{"trials":1559,"activeCount":99},[],{"trials":1561,"activeCount":99},[1562],{"nctId":1563,"briefTitle":1564,"status":575,"phases":1565,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":99,"conditions":1569,"interventions":1573},"NCT05497934","The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear",[87],"2023-10-01","2024-03-31","2022-10-01",[1570,1571,1572,141],"Tympanosclerosis","Thickened Ears","Healthy",[1556],{"trials":1575,"activeCount":99},[],{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"trials":1581,"activeCount":99},[],{"intervention":865,"totalTrials":603,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1590,"PHASE4":1592,"NA":1598},{"trials":1585,"activeCount":99},[],{"trials":1587,"activeCount":99},[],{"trials":1589,"activeCount":99},[],{"trials":1591,"activeCount":99},[],{"trials":1593,"activeCount":99},[1594],{"nctId":855,"briefTitle":856,"status":563,"phases":1595,"primaryCompletion":858,"completion":858,"start":859,"enrollment":860,"conditions":1596,"interventions":1597},[90],[862],[842,864,865],{"trials":1599,"activeCount":99},[1600],{"nctId":1601,"briefTitle":1602,"status":563,"phases":1603,"completion":1493,"start":1604,"enrollment":1351,"conditions":1605,"interventions":1610},"NCT00245375","A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery",[91],"2005-01",[1606,1607,1608,1609],"Laparoscopic Cholecystectomy","Inguinal Hernia","Abdominal Hernia","Umbilical Hernia",[865,1611],"Combination Tylenol and Ibuprofen",{"intervention":1613,"totalTrials":95,"cells":1614},"Medical Management Alone Arm",{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1616,"activeCount":99},[],{"trials":1618,"activeCount":99},[],{"trials":1620,"activeCount":99},[],{"trials":1622,"activeCount":99},[],{"trials":1624,"activeCount":99},[],{"trials":1626,"activeCount":99},[1627],{"nctId":1628,"briefTitle":1629,"status":575,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1631,"enrollment":99,"conditions":1632,"interventions":1635},"NCT04998513","Medical Versus Surgical Treatment for Peritonsillar Abscesses",[91],"2022-01",[1633,1634],"Peritonsillar Abscess","Surgical Incision",[1613],{"intervention":1611,"totalTrials":95,"cells":1637},{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1642,"PHASE3":1644,"PHASE4":1646,"NA":1648},{"trials":1639,"activeCount":99},[],{"trials":1641,"activeCount":99},[],{"trials":1643,"activeCount":99},[],{"trials":1645,"activeCount":99},[],{"trials":1647,"activeCount":99},[],{"trials":1649,"activeCount":99},[1650],{"nctId":1601,"briefTitle":1602,"status":563,"phases":1651,"completion":1493,"start":1604,"enrollment":1351,"conditions":1652,"interventions":1653},[91],[1606,1607,1608,1609],[865,1611],{"intervention":1655,"totalTrials":95,"cells":1656},"Administration of 123Iodine MIBG",{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1658,"activeCount":99},[],{"trials":1660,"activeCount":99},[],{"trials":1662,"activeCount":99},[],{"trials":1664,"activeCount":99},[],{"trials":1666,"activeCount":99},[],{"trials":1668,"activeCount":99},[1669],{"nctId":1670,"briefTitle":1671,"status":575,"phases":1672,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":99,"conditions":1675,"interventions":1677},"NCT01912040","Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use",[],"2018-12","2006-07",[1676],"Adrenergic Pathology",[1655],{"intervention":1679,"totalTrials":95,"cells":1680},"Alteplase",{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1685,"PHASE3":1687,"PHASE4":1689,"NA":1691},{"trials":1682,"activeCount":99},[],{"trials":1684,"activeCount":99},[],{"trials":1686,"activeCount":99},[],{"trials":1688,"activeCount":99},[],{"trials":1690,"activeCount":99},[],{"trials":1692,"activeCount":99},[1693],{"nctId":1694,"briefTitle":1695,"status":563,"phases":1696,"primaryCompletion":1697,"completion":1698,"start":618,"enrollment":521,"conditions":1699,"interventions":1701},"NCT02474810","Intensive Versus Standard Hemodialysis CVC Dysfunction Protocol",[91],"2015-07","2015-09",[1700],"Chronic Renal Insufficiency",[1679],{"intervention":1703,"totalTrials":95,"cells":1704},"Dabigatran.",{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1711,"PHASE4":1713,"NA":1715},{"trials":1706,"activeCount":99},[],{"trials":1708,"activeCount":99},[],{"trials":1710,"activeCount":99},[],{"trials":1712,"activeCount":99},[],{"trials":1714,"activeCount":99},[],{"trials":1716,"activeCount":99},[1717],{"nctId":1718,"briefTitle":1719,"status":575,"phases":1720,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":99,"conditions":1724,"interventions":1726},"NCT01810237","Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy",[91],"2013-07","2013-09","2013-03",[1725],"Venous Thromboses",[1703],{"intervention":1728,"totalTrials":95,"cells":1729},"Botox Injectable Product",{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1736,"PHASE4":1738,"NA":1740},{"trials":1731,"activeCount":99},[],{"trials":1733,"activeCount":99},[],{"trials":1735,"activeCount":99},[],{"trials":1737,"activeCount":99},[],{"trials":1739,"activeCount":99},[],{"trials":1741,"activeCount":99},[1742],{"nctId":1743,"briefTitle":1744,"status":715,"phases":1745,"primaryCompletion":1746,"completion":1746,"start":1747,"enrollment":1748,"conditions":1749,"interventions":1752},"NCT04383912","Onabotulinum Toxin A in Direct Brow Lift",[91],"2024-07","2020-11-18",16,[1750,1751],"Direct Brow Lift","Scarring",[1728],{"intervention":1754,"totalTrials":95,"cells":1755},"DNA and whole transcriptome mRNA sequencing",{"EARLY_PHASE1":1756,"PHASE1":1758,"PHASE2":1760,"PHASE3":1762,"PHASE4":1764,"NA":1766},{"trials":1757,"activeCount":99},[],{"trials":1759,"activeCount":99},[],{"trials":1761,"activeCount":99},[],{"trials":1763,"activeCount":99},[],{"trials":1765,"activeCount":99},[],{"trials":1767,"activeCount":99},[1768],{"nctId":1769,"briefTitle":1770,"status":563,"phases":1771,"primaryCompletion":1772,"completion":1772,"start":1773,"enrollment":1774,"conditions":1775,"interventions":1776},"NCT05111067","Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity",[],"2023-12-01","2021-12-01",120,[449],[1754],{"intervention":1778,"totalTrials":95,"cells":1779},"Caffeine",{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1786,"PHASE4":1788,"NA":1790},{"trials":1781,"activeCount":99},[],{"trials":1783,"activeCount":99},[],{"trials":1785,"activeCount":99},[],{"trials":1787,"activeCount":99},[],{"trials":1789,"activeCount":99},[],{"trials":1791,"activeCount":99},[1792],{"nctId":1793,"briefTitle":1794,"status":563,"phases":1795,"primaryCompletion":1796,"completion":1797,"start":1798,"enrollment":180,"conditions":1799,"interventions":1800},"NCT02832401","The Impact of Caffeine on Cognition in Schizophrenia",[91],"2018-08-02","2019-08-02","2016-09-02",[33,1778],[1778]]